By Len Zehr Closely-held DxTerity has developed the first affordable diagnostics platform for at-home monitoring of autoimmune disease activity and response to drug treatment, with tests that use longitudinal gene...
By Len Zehrs Swiss-based GeNeuro (Euronext Paris: CH0308403085 – GNRO) is leveraging the biology of human endogenous retroviruses (HERVs) to stop the causes of neurodegenerative and autoimmune diseases, such as multiple...
By Len Zehr Closely-held Parvus Therapeutics is developing a broad therapeutic platform, called Navacims, to treat autoimmune diseases through in vivo expansion and activation of disease-specific regulatory T-cells (T...